News Details

NEW ORLEANS – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today introduced the Series 275 HRes^™ Liquid Chromatography (LC) System at PITTCON^® 2008, Booth #2555. With this system, LC users have the opportunity to increase throughput and improve resolution using small particle-size column technology at ultra-high pressure ranges. The system was designed to support quality assurance/quality control (QA/QC) in the food and beverage, environmental, pharmaceutical and materials testing markets.

“PerkinElmer is committed to continually enhancing our chromatography offerings,” said Eric Ziegler, Vice President of Chromatography, PerkinElmer Life and Analytical Sciences. “This dedicated system is a complement to our LC offerings in response to the user need for increased throughput with greater speed, resolution and performance.”

Ziegler noted that the system's new Brownlee^™ HRes LC Column technology features newly developed small particles for high resolution and speed of separation. “The need for increased resolution is growing across the different market segments. With the Series 275 HRes^™ LC System, customers have the opportunity to re-think laboratory workflow and efficiency,” Ziegler added.

The system also includes the new Series 275 Autosampler, which allows for greater automation and repeatability in the critical injection phase. A new Series 275 Binary Micro Pump supports the newly developed small particle/high resolution LC columns. For ease of transition to this new technology, the system is controlled and fully integrated with PerkinElmer's TotalChrom^® software and provides 21 CFR Part 11 compliance.

For more information, visit www.perkinelmer.com/Series275HResLC.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers' demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release. PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

“Brownlee” is a trademark of the respective party. “PITTCON” is a registered trademark of its owner.

For further information regarding PerkinElmer, please contact:

Media Contact:
Ellen Wein
Euro RSCG Worldwide PR
(412) 456-0986
or
Lesley Sillaman
Euro RSCG Worldwide PR
(412) 456-7839